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ReportsIntracameral Chemotherapy for
Globe Salvage in
Retinoblastomawith Secondary
Anterior Chamber InvasionThe presence of anterior chamber seeding (ACS), whether pri-
mary (1%) or secondary, is commonly treated by enucleation.
Considering the new frontiers of conservative management of
very advanced retinoblastoma, the reported incidence of second-
ary ACS leading to conservative failure has progressed from 6%
after chemoreduction to 67% after intra-arterial chemotherapy
(IAC).1
Anterior chamber seeding is considered an intractable form of
retinoblastoma regardless of the treatment used because of the
hypoxic radio-resistant nature of the seeds and inability to reach
tumoricidal concentrations in the aqueous using known routes of
chemotherapy administration. Successful attempts to treat ACS
were reported only recently and concerned patients with primary
ACS in diffuse anterior retinoblastoma of retinal origin by intra-
cameral chemotherapy (ICC)2 and of extra-retinal origin by
brachytherapy.3
In this retrospective review approved by the ethical committee
of Vaud, Switzerland (authorization no. 2016-00149), 12 consec-
utive patients with ACS treated with ICC were identiﬁed between
November 2011 and October 2016. One case was excluded with
primary ACS class III (pseudo-hypopion) resulting from anterior
diffuse retinoblastoma published previously2 with an event-free
follow-up of 5.5 years. The study population consisted of 11
eyes with secondary ACS from 11 heavily pretreated patients for
whom advised enucleation was refused by the parents, including 10
patients with relapse referred from other centers. There were 4 eyes
with unilateral and 7 eyes with bilateral retinoblastoma, of which 4
were remaining eyes after previous enucleation of the fellow eyes.
The demographic characteristics and the treatment received before
ICC, as well as ACS classiﬁcation, relapses, and concomitant ul-
trasound biomicroscopy features, are shown in Table S1 (available
at www.aaojournal.org).
Anterior chamber seeding was classiﬁed as class I in 5 eyes,
class II in 5 eyes, and class III in 1 eye (Fig 1AeF). According to
the integrity of anterior hyaloid, 2 distinct mechanisms of tumor
progression into the anterior segment could be distinguished: (1)
transhyaloid inﬁltration into the posterior chamber secondary to
vitreous seeds attached to the anterior hyaloid in 3 eyes (no
peripheral primary or secondary retinal tumors) or to the anterior
progression of a peripheral parietal tumor overlying the pars
plana in 4 eyes (Fig 1G, I); and (2) invasion via a disrupted
anterior hyaloid of iatrogenic origin, that is, pars plana
vitrectomy (Fig 1K, L), and clear corneal intracapsular
lensectomy in 2 eyes each. Anterior chamber seeding was
isolated (9 eyes) or associated with an anterior uveal inﬁltration
(2 eyes) as assessed by ultrasound biomicroscopy.
Intracameral chemotherapy with melphalan was administered
(concentration of 15 or 20 mg/ml, the lower concentration usedinitially and the higher concentration used in case of ACS relapse/
persistence) as previously described.2 All but 3 eyes (vitrectomized
with silicone oil or postintracapsular lensectomy, see Table S1,
available at www.aaojournal.org) received concomitant
intravitreal chemotherapy at least once via the pars plana with 20
to 30 mg of melphalan at a concentration of 200 mg/ml to treat
the underlying vitreous disease or, if absent, to prevent cross-
contamination between the aqueous and the vitreous. Tumor con-
trol was monitored clinically by slit-lamp examination as well as in
the iterative aqueous taps by cytopathology and by cell culture
when available.2 Intracameral chemotherapy was continued as long
as the cytopathology or cell culture remained positive and at least 1
additional injection was given after a negative result.
Complete aqueous seeding regression was initially obtained in
all eyes after a mean of 0.7 months (range, 0.2e1.3) as assessed
clinically and by negative cytopathology and cell culture, after a
mean number of 4.3 injections (range, 2e7) with a mean dose of
6.3 mg (range, 2.9e15) per injection. Higher doses corresponded to
a greater quantity of aqueous humor withdrawn in cases with
disrupted hyaloid (mean 0.46 ml compared with 0.24 ml with the
hyaloid intact), indirectly conﬁrming disruption of the hyaloid.
Anterior chamber seeding class I required notably less mean 3.2
injections compared with 5.2 injections in classes II and III.
Treatment during or after ICC, ICC-related complications,
globe preservation, functional results, and histopathology of the
enucleated eyes are summarized in Table S2 (available at
www.aaojournal.org).
Eye preservation was achieved in only 25% (1/4) of cases with
disrupted anterior hyaloid versus 71% (5/7) with intact anterior
hyaloid, including all 4 remaining eyes after previous enucleation
of the fellow eyes. The absence of anterior hyaloid in the former
group of 4 eyes could have inﬂuenced negatively the outcome by 2
mechanisms: (1) by preventing the achievement of a tumoricidal
concentration in the anterior segment through dilution of the ICC
in the posterior segment or (2) by favoring or maintaining cross-
contamination between the posterior and anterior segment. In the
latter group of 7 eyes with apparently intact anterior hyaloid, 2
eyes (cases 5 and 10) underwent enucleation for progressive dis-
ease after a retention time of 2.8 and 1.0 months, respectively,
after the ﬁrst ICC. Failure in case 5 was likely related to the
extreme aggressiveness of the N-myc ampliﬁcation genotype,
whereas in case 10, secondary enucleation was decided on the
basis of disease progression in an eye devoid of visual potential
and with an obscured optic disk. In total, enucleation was per-
formed in 5 cases after a mean retention time of 8.8 months (range,
1.0e20.7). In 1 eye (case 5), histopathology revealed higher risk
factors, supporting the indication for systemic adjuvant chemo-
therapy (Table S2, available at www.aaojournal.org) and remained
event-free over a follow-up of 24 months. Patient number 1
received 2 courses of carboplatin-etoposide intravenous chemo-
therapy, considering that transconjunctival pars plana vitrectomy
had been performed in the context of unsuspected diffuse inﬁl-
trating retinoblastoma before his referral. Conservative treatment615
Figure 1. Anterior chamber photography with aqueous seeding class I (ﬁrst
row: case 2), class II (second row: case 3), and class III (third row: case 11)
before (A, C, E) and after (B, D, F) ICC. Note the diffuse iris hypochromic
heterochromia after ICC (B, D). The pupillary deformation (C, D) is iat-
rogenic after intracapsular extraction of the lens. GeL, RetCam images and
ultrasound biomicroscopy longitudinal sections featuring intact (GeJ) or
disrupted (K, L) anterior hyaloid in 2 phakic eyes from cases 2 and 1,
respectively (Tables S1 and S2, available at www.aaojournal.org). G, I, Case
2 before treatment: retinal tumor recurrence across the ora serrata (black and
white asterisks) over the pars plana with presumed transhyaloidal invasion of
the posterior chamber (black and white squares) via Petit’s canal.H, J, Case 2
after treatment (ICC and brachytherapy) showing complete response (H):
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616was attempted given that visual function was preserved (20/30)
with fovea and optic nerve intact. No adjuvant systemic chemo-
therapy was given to any of the other patients, considering that the
prognostic value of aqueous seeding or anterior uveal invasion
such as iris or corpus ciliaris involvement is no longer considered a
high risk for metastasis.4,5 Salvaged eyes have a mean event-free
follow-up of 17 months (range, 4e36). All patients are alive
without metastasis at a mean follow-up of 24 months (range,
12e54).
In conclusion, ICC concomitant with other treatments, offers an
alternative to enucleation in selected cases of retinoblastoma with
secondary ACS. Although these are encouraging results, further
studies with longer follow-up are necessary to assess the safety and
long-term efﬁcacy of this new targeted modality.
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francis.munier@fa2.ch.regression of retinal tumor with posterior chamber tumor-free and no
apparent interruption of the anterior hyaloid (J). K, L, Anterior segment
RetCam image of case 1 showing the presence of silicone oil and dust (K).
Silicone oil in the anterior and posterior chambers is shown on longitudinal
ultrasound biomicroscopy section (L). Note 2 visible spheres in the pos-
terior chamber at the surface of the highly echogenic silicone bubble.
Hashtag (Y) indicates the thickened retina up to the ora serrata, corre-
sponding to anterior extension of the diffuse inﬁltrating retinoblastoma.
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Treatment-Refractory Ocular
Surface Squamous NeoplasiaOcular surface squamous neoplasia (OSSN) is deﬁned as a group of
dysplastic, preinvasive, and malignant squamous lesions involving
the cornea and conjunctiva. Management of OSSN varies, and
typically is governed by lesion size, distribution, and pathologic
severity. Treatment incorporates surgical excision with adjuvant
cryotherapy to margins, topical chemotherapy, or both, the latter
commonly withmitomycin C and 5-ﬂuorouracil.1More recently, the
application of topical interferon alfa-2b has been used successfully
for treating OSSN. Yet despite the prevailing contemporary standard
of care, recurrence remains high at up to 53% of cases.1
Human papilloma virus (HPV) has been implicated as an
etiologic agent in the pathogenesis of OSSN. We demonstrated that
approximately 6.5% of OSSN specimens showed positive results
for a high-risk HPV serotype (HPV-16), detection of which
corresponded with more severe pathologic OSSN types, namely
squamous cell carcinoma.2 Cidofovir is an antiviral with activity
against different double-stranded DNA viruses, including HPV,
and has been used previously to treat HPV-associated lesions.3
This single-center, retrospective, interventional case series
recruited 6 patients with treatment-refractory OSSN. Patients
satisﬁed inclusion criteria if they possessed biopsy-proven
diagnoses of OSSN before cidofovir administration and were
treatment refractory to surgery, adjuvant cryotherapy, and an
additional topical agent. Patients were excluded if additional or
alternate diagnoses on biopsy were identiﬁed. Formalin-ﬁxed
parafﬁn-embedded tissues and ThinPrep (Cytyc Corp; Marl-
borough, MA) specimens were analyzed for HPV presence using a
hybrid-capture assay.2 Details of our HPV detection methodology
can be found in Appendix 1 (available at www.aaojournal.org).
A chart review of all patients treated with topical cidofovir
(2.5 mg/ml thrice daily) between 2014 and 2016 was conducted.
Topical cidofovir vials were compounded at an external pharmacy,
and patients were treated for at least 4 weeks. Tumor regression
was diagnosed with slit-lamp biomicroscopy and photography and,
if required, repeat histopathologic analysis. Recurrence was
monitored after ﬁrst documented instance of tumor resolution.
Institutional ethics review board approval was obtained for thisstudy. This study was approved by the South-Eastern Sydney Area
Health Service Human Research Ethics Committee (Eastern Sec-
tion) 15/200 and was performed in accordance with the tenets of
the Declaration of Helsinki.
Five men and 1 woman (mean age, approximately 82.1 years)
with treatment-refractory OSSN were treated with 2.5 mg/ml
topical cidofovir (1 drop thrice daily) for 4 to 9 weeks (Table 1;
Fig S1, available at www.aaojournal.org). Patients responded to
topical cidofovir at varying times, with ﬁrst observation for
tumor clearance ranging between 24 and 60 days. Patients thus
continued topical cidofovir until the end of the week after tumor
clearance was ﬁrst observed. Our patients had been previously
managed for 1337 days (mean) of excisional biopsy, adjuvant
cryotherapy, topical interferon alfa-2b and retinoic acid, intrale-
sional interferon, oral cimetidine, topical mitomycin C cycles, or a
combination thereof before commencing topical cidofovir. A mean
tumor-free follow-up of approximately 454 days (range, 222e876
days) was achieved from our case series of 6 patients, with tumor
clearance identiﬁed in 5 of 6 eyes affected and no observable
recurrence even at present. One eye demonstrated conjunctivitis
and punctal stenosis during treatment with cidofovir that settled on
treatment cessation. Two lacrimal punctum plugs were placed as
prophylaxis (patient 4). All 5 treatment specimens obtained before
cidofovir administration were analyzed for high-risk HPV pres-
ence, and HPV-16 was identiﬁed in 1 patient (patient 4) only. No
HPV detection after treatment was performed.
Conundrums that prevent optimal OSSN control include invisible
disease with lacrimal system metastases and multifocal limbal dis-
ease. Topical therapy represents a solution for mitigating these, being
able to treat the entirety of the ocular surface and inconspicuous
spread within the lacrimal drainage system. Unfortunately, contem-
porary topical chemotherapeutic agent application (mitomycinCor 5-
ﬂuorouracil drops) is associated with transient ocular adverse effects,
and occasionally destructive sight-limiting complications.1 Topical
interferon alfa-2b monotherapy represents an alternative with a
decreased side-effect proﬁle and improved tumor-free follow-up.1
We previously demonstrated in an 89-patient study excellent tumor
clearance of approximately 97.8% and tumor-free follow-up of
approximately 51.5monthswhen using topical interferon alfa-2b and
all-trans retinoic acid combination therapy.4 Despite the excellent
results, approximately 2% of patients demonstrated recurrent
disease, and we hypothesized that a viral coinfection with HPV
may be contributing toward therapy-resistant diseases.
We observed only 1 case each of transient conjunctivitis and
punctal stenosis, both of which resolved after treatment cessation and
lacrimal punctum plugging. Because of the known toxicity of cido-
fovir, other antiviral agents may bewarranted that have less impact on
the lacrimal drainage apparatus, or lacrimal plugs may be used as an
adjunct. We observed that most of our patients (n ¼ 5) showed
complete resolution after topical cidofovir applicationwith an average
tumor-free follow-up of approximately 454 days. More severe grades
of OSSN (cornealeconjunctival intraepithelial neoplasia II/III; pa-
tients 2e5) weremore likely to respond to topical cidofovir compared
with lower-grade tumors (cornealeconjunctival intraepithelial
neoplasia I; patient 1),whichmaybe the result of a correlation between
more severe tumor types and viral coinfection.2 However, 1 patient
(patient 6) demonstrated observable tumor clearance despite
histopathologic identiﬁcation as a benign papilloma.
Only 1 specimen obtained before cidofovir treatment showed
positive results for HPV-16, although there exist factors that may have617
